25 June, 2020
Davis Polk advised Genetron Holdings Limited on its SEC-registered initial public offering of 16,000,000 American Depositary Shares. Each ADS represents five ordinary shares. Genetron has granted the underwriters an option to purchase up to an additional 2,400,000 ADSs. The total gross proceeds for the SEC-registered initial public offering are approximately $256 million, assuming the underwriters do not exercise their option to purchase any over-allotment ADSs. The ADSs are listed on the Nasdaq Global Market under the symbol “GHT”.
Genetron is a leading precision oncology platform company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. It has developed a comprehensive product and service portfolio that covers the full-cycle of cancer care from early screening, to diagnosis and treatment recommendations, to continuous monitoring and continuous care.
The Davis Polk corporate team included partners Li He and James C. Lin, counsel – registered foreign lawyer Xuelin (Steve) Wang and registered foreign lawyer Xin (Sheen) Xu. Counsel Alon Gurfinkel and associate Omer Harel provided tax advice. Associate J. Taylor Arabian provided 1940 Act Advise. Members of the Davis Polk team are based in the Hong Kong, London and New York offices.
